期刊文献+

苯那普利对糖尿病大鼠肾脏病变保护作用机制的研究 被引量:4

Protective effect of benazepril on diabetic nephropathy in rats
在线阅读 下载PDF
导出
摘要 目的:探讨血管紧张素转换酶抑制剂苯那普利对糖尿病大鼠肾脏病变的保护作用及其机制。方法:24只健康雄性Wistar大鼠随机分成正常对照组(NC组,n=8)、糖尿病未治疗组(DM组,n=8)和糖尿病苯那普利治疗组(DL组,n=8)。应用链脲佐菌素(STZ)诱导糖尿病模型,造模成功后,用苯那普利10 mg/(kg.d)对DL组进行治疗性灌胃,其余2组均用等量自来水灌胃。4周后,将所有大鼠一次性处死,摘取肾脏。用明胶酶谱分析法检测肾组织基质金属蛋白酶-2(MMP-2)活性;用免疫组化法检测肾组织IV胶原(IV-C)、MMP-2、基质金属蛋白酶组织抑制因子-2(TIMP-2)蛋白的表达,并利用计算机图像分析系统进行半定量图像分析;用逆转录-聚合酶链反应测定肾组织中MMP-2、TIMP-2mRNA的表达。同时进行肾组织透射电镜检查。结果:糖尿病组与正常对照组比较,尿量、Upro、BUN、Ccr显著增高(P均<0.01),肾小球MMP-2活性、mRNA及蛋白表达均降低,而TIMP-2 mRNA及蛋白表达升高,IV-C胶原表达亦增加;苯那普利治疗组Upro、BUN、Ccr较糖尿病组均有不同程度的降低(P均<0.05),肾小球MMP-2活性、mRNA及蛋白表达升高,而TIMP-2 mRNA及蛋白表达I、V-C胶原表达均减少。结论:苯那普利对糖尿病大鼠肾功能和肾组织形态学具有保护作用,其作用机制可能与上调肾小球MMP-2的表达和下调TIMP-2的表达,提高MMP-2活性,从而减轻肾小球细胞外基质沉积有关。 Objective: To investigate the protective effect and possible mechanisms of benazepril on diabetic nephropathy(DN)in rats. Methods: Twenty-four healthy male Wistar rats were randomly divided into normal control group (NC group), diabetic group untreated with benazepril (DM group) and diabetic group treated with benazepril (DL group). The DN model was established following intraperitoneal injection of streptozecin (60 mg·kg^-1 ). Benazepril ( 10 mg·kg^-1·d^-1 ) was given to the DL group for 4 weeks, whereas the same milliliter water was given to the other two groups. At the end of 4 weeks, renal function was evaluated with 24-hour urinary protein (Upro), clearance of ereatinin (Cer) and blood urea nitrogen (BUN), the MMP-2 activities were determined by gelatin zymography, the expression levels of MMP-2, TIMP-2 and collagen Ⅳ (Ⅳ-C) protein in the kidney tissues were determined by immunohistochemistry method and the gene expressions of MMP-2 and TIMP-2 were measured by RTPCR. Results: Compared with NC group, DM group had an increase of serum BUN, Upro and Cer values, a decrease of mRNA and enzymatic activity and proteins of MMP-2 but an increase of the Ⅳ-C and TIMP-2 expressions. All the diabetes-associated changes in renal function and MMP/TIMP were attenuated by benazepfil treatment with reduced Ⅳ-C accumulation. Conclusion: Benazepfil has some protective effect on diabetic nephropathy, which may relate with the inhibition of excessive deposition of glomeruli extracellular matrix by up-regulating the MMP-2 and downregulating the TIMP-2 expressions.
出处 《山东大学学报(医学版)》 CAS 北大核心 2006年第4期404-409,共6页 Journal of Shandong University:Health Sciences
基金 山东省自然科学基金资助课题(Y2002C35)
关键词 血管紧张素转换酶抑制药 糖尿病肾病 基质金属蛋白酶2 金属蛋白酶组织抑制剂2 大鼠 Wistar Angiotensin eonvesting enzyme inhibitors Diabetic nephmpathies Matrix metalloproteinase 2 Tssue inhibitor of metalloproteinases Rats, Wistar
  • 相关文献

参考文献12

  • 1Border WA,Noble NA.Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy[J].Kidney Int,1998,54:1 390-1 391.
  • 2Gilbert RE,Cox A,Wu LL,et al.Expression of transforming growth factor-betal and type Ⅳ collagen in the renal tubulointerstitium in experimental diabetes:effects of ACE inhibition[J].Diabetes,1998,47:414-422.
  • 3Nakamura T,Takahashi T,Fukui M,et al.Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats[J].Am Soc Nephrol,1995,5:1 492-1 497.
  • 4Suzuki D,Miyazaki M,Jinde K,et al.In situ hybridization studies of matrix metalloproteinase-3,tissue inhibitor of metalloproteinase-1 and type Ⅳ collagen in diabetic nephropathy[J].Kidney Int,1997,52(1):111-119.
  • 5Mclennan SV,Martell SK,Yue DK.Effects of mesangium glycation on matrix metalloproteinase activities:possible role in diabetic nephropathy[J].Diabetes,2002,51 (9):2 612-2 618.
  • 6Mclennan SV,Kelly DJ,Cox AJ,et al.Decreased matrix degradation in diabetic nephropathy:effects of ACE inhibition on the expression and activities of matrix metalloproteinases[J].Diabetologia,2002,45(2):268-275.
  • 7Alderson NL,Chachich ME,Frizzel N,et al.Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat[J].Diabetologia,2004,47(8):1 385-1 395.
  • 8Allen TJ,Cao Z,Youssef S,et al.Role of angiotensin Ⅱ and bradykinin in experimental diabetic nephropathy.Functional and structural studies[J].Diabetes,1997,46:1 612-1 618.
  • 9Singh R,Alavi N,Singh AK,et al.Role of angiotensin Ⅱ in glucose-induced inhibition of mesangial matrix degradation[J].Diabetes,1999,48:2066-2073.
  • 10Laffel LM,McGill JB,Gans DJ.The beneficial effect of ACE inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria.North America Microalbuminuria Study Group[J].Am Med,1995,99:497-504.

同被引文献19

  • 1印晓星,张银娣.糖尿病肾病的发病机理及其药物治疗[J].广东药学院学报,2004,20(5):541-544. 被引量:31
  • 2Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes [J]. J HumHypertens, 2003, 17 (1): 7- 12.
  • 3Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomendar hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathyin patients [ J ]. Diabetes, 2005,54 (7) : 2206 -2211.
  • 4Sarafidis PA, Lasaridis AN, Nilsson PM, et al. The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetesmellitus and hypertension [ J ]. Am J Hypertens,2005, 18 (2 Pt 1) : 227 -234.
  • 5Gongidi V, Ring C, Moody M, et al. SPARC -like 1 regulates the terminal phase of radial glia - guided migration in the cerebral cortex[J]. Neuron, 2004, 41 (1) : 57 - 69.
  • 6Law AK, Pencea V, Buck CR, et al. Neurogenesis and neuronalmigration in the neonatal rat forebrain anterior subventricular zone do not require GFAP - positive astrocytes[J]. Dev Biol, 1999, 216 (2) : 622 -634.
  • 7Li HS, Chen JH, WuW, et al. Vertebrate slit, a secreted ligand for the transmembrane protein roundabout, is a repellent for olfactory bulb axons [ J ]. Cell, 1999, 96 (6) : 807 -818.
  • 8Haffncr SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus[ J ]. Circulation, 2002, 106 (6) :679 - 684.
  • 9Eckel RH, Alberti KG, Grundy SM, et al. The metabolic syndrome [J]. Lancet, 2010, 375(9710):181 -183.
  • 10De Jager J, Dekker JM, Kooy A, et al. Endothelial dysfunction and low - grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes:the Hoorn study[J]. Arterioscler Thromb Vasc Biol, 2006, 26 (5) : 1086 - 1093.

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部